Xenetic Biosciences Inc. (XBIO)’s Financial Results Comparing With Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)

Xenetic Biosciences Inc. (NASDAQ:XBIO) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenetic Biosciences Inc. 7.50M 2.55 1.22M -0.12 0.00
Intercept Pharmaceuticals Inc. 164.21M 19.93 332.51M -12.40 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Xenetic Biosciences Inc. and Intercept Pharmaceuticals Inc.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences Inc. -16.27% -9.5% -7%
Intercept Pharmaceuticals Inc. -202.49% -644.1% -65.2%

Risk & Volatility

Xenetic Biosciences Inc. is 2.00% more volatile than Standard & Poor’s 500 due to its 1.02 beta. From a competition point of view, Intercept Pharmaceuticals Inc. has a -1 beta which is 200.00% less volatile compared to Standard & Poor’s 500.

Liquidity

Xenetic Biosciences Inc.’s Current Ratio is 1.7 while its Quick Ratio is 1.7. On the competitive side is, Intercept Pharmaceuticals Inc. which has a 6 Current Ratio and a 6 Quick Ratio. Intercept Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Xenetic Biosciences Inc.

Analyst Recommendations

Recommendations and Ratings for Xenetic Biosciences Inc. and Intercept Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Xenetic Biosciences Inc. 0 0 0 0.00
Intercept Pharmaceuticals Inc. 0 1 10 2.91

Meanwhile, Intercept Pharmaceuticals Inc.’s consensus price target is $166.4, while its potential upside is 50.79%.

Institutional and Insider Ownership

The shares of both Xenetic Biosciences Inc. and Intercept Pharmaceuticals Inc. are owned by institutional investors at 0.8% and 65.1% respectively. About 64.63% of Xenetic Biosciences Inc.’s share are held by insiders. On the other hand, insiders held about 23.3% of Intercept Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xenetic Biosciences Inc. -24.24% -4.21% -12.59% 55.28% 15.74% 30.31%
Intercept Pharmaceuticals Inc. -4.44% -7.4% -7.2% 39.22% 72.45% 81.43%

For the past year Xenetic Biosciences Inc.’s stock price has smaller growth than Intercept Pharmaceuticals Inc.

Summary

Xenetic Biosciences Inc. beats Intercept Pharmaceuticals Inc. on 6 of the 11 factors.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.